Dexlido Kit also known as Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine is a human prescription drug labeled by 'Asclemed Usa, Inc.'. National Drug Code (NDC) number for Dexlido Kit is 76420-767. This drug is available in dosage form of Kit. The names of the active, medicinal ingredients in Dexlido Kit drug includes . The currest status of Dexlido Kit drug is Active.

Purpose: purpose: first aid antiseptic to help prevent skin infection in minor cuts, scrapes and burns. for preparation of the skin prior to surgery. helps reduce bacteria that can potentially cause skin infections.

Purpose antiseptic

Dexlido kit dexamethasone sodium phosphate, lidocaine hydrochloride, povidine iodine dexamethasone sodium phosphate dexamethasone sodium phosphate sodium citrate citric acid monohydrate sodium hydroxide dexamethasone sodium phosphate dexamethasone dexamethasone phosphate lidocaine hydrochloride lidocaine hydrochloride sodium chloride water sodium hydroxide hydrochloric acid lidocaine hydrochloride lidocaine lidocaine hydrochloride anhydrous povidine iodine povidine iodine glycerin polysorbate 80 sodium citrate sodium phosphate, dibasic, anhydrous citric acid acetate water povidone-iodine iodine isopropyl alcohol isopropyl alcohol water isopropyl alcohol isopropyl alcohol

Clinically significant drug interactions the administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. concurrent use of these agents should generally be avoided. in situations when concurrent therapy is necessary, careful patient monitoring is essential. concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

Indications and usage by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to ti Read more...

Indications and usage lidocaine hydrochloride injection is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

For use as an first aid antiseptic pre-operative skin preperation

Uses for first aid to decrease germs in minor cuts scrapes burns for preparation of the skin prior to injection

Warnings because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug. anaphylactoid and hypersensitivity reactions have been reported for dexamethasone sodium phosphate injection (see adverse reactions ). corticosteroids may exacerbate systemic fungal infections and, therefore, should not be used in the presence of such infections unless they are needed to control drug reactions due to amphotericin b. moreover, there have been cases reported in which concomitant use of amphotericin b and hydrocortisone was followed by cardiac enlargement and congestive failure. in patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. drug-induced secondary adrenocortical insuff Read more...

Serious neurologic adverse reactions with epidural administration serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. these serious neurologic events have been reported with and without use of fluoroscopy. the safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use.

Usage in pregnancy since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.

Warnings lidocaine hydrochloride injection for infiltration and nerve block should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies that might arise from the block to be employed and then only after ensuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary equipment and the personnel needed for proper management of toxic reactions and related emergencies (see also adverse reactions and precautions ). delay in proper management of dose-related toxicity, underventilation from any cause and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. methemoglobinemia cases of methemoglobinemia have been reported in association with local anesthetic use. although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary com Read more...

Warnings: section text for external use only

Warnings for external use only flammable - keep away from fire or flame do not use with electrocautery procedures when using this product do not get into eyes apply over large areas of the body in case of deep or puncture wounds, animal bites or serious burns consult a doctor stop use and ask a doctor if condition persists or gets worse or lasts for more than 72 hours do not use longer than 1 week unless directed by a doctor keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Warnings because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug. anaphylactoid and hypersensitivity reactions have been reported for dexamethasone sodium phosphate injection (see adverse reactions ). corticosteroids may exacerbate systemic fungal infections and, therefore, should not be used in the presence of such infections unless they are needed to control drug reactions due to amphotericin b. moreover, there have been cases reported in which concomitant use of amphotericin b and hydrocortisone was followed by cardiac enlargement and congestive failure. in patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. drug-induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. this type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. if the patient is receiving steroids already, dosage may have to be increased. since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. corticosteroids may mask some signs of infection, and new infections may appear during their use. there may be decreased resistance and inability to localize infection when corticosteroids are used. moreover, corticosteroids may affect the nitroblue-tetrazolium test for bacterial infection and produce false negative results. in cerebral malaria, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of coma and a higher incidence of pneumonia and gastrointestinal bleeding. corticosteroids may activate latent amebiasis. therefore, it is recommended that latent or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea. prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. these effects are less likely to occur with the synthetic derivatives except when used in large doses. dietary salt restriction and potassium supplementation may be necessary. all corticosteroids increase calcium excretion. administration of live virus vaccines, including smallpox, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids. if inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained. however, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for addison’s disease. patients who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. in such children or adults who have not had these diseases, particular care should be taken to avoid exposure. the risk of developing a disseminated infection varies among individuals and can be related to the dose, route and duration of corticosteroid administration as well as to the underlying disease. if exposed to chickenpox, prophylaxis with varicella zoster immune globulin (vzig) may be indicated. if chickenpox develops, treatment with antiviral agents may be considered. if exposed to measles, prophylaxis with immune globulin (ig) may be indicated. (see the respective package inserts for vzig and ig for complete prescribing information). the use of dexamethasone sodium phosphate injection in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. if corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. during prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients. serious neurologic adverse reactions with epidural administration serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. these serious neurologic events have been reported with and without use of fluoroscopy. the safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use. usage in pregnancy since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.

Serious neurologic adverse reactions with epidural administration serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. these serious neurologic events have been reported with and without use of fluoroscopy. the safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use.

Usage in pregnancy since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.

Warnings lidocaine hydrochloride injection for infiltration and nerve block should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies that might arise from the block to be employed and then only after ensuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary equipment and the personnel needed for proper management of toxic reactions and related emergencies (see also adverse reactions and precautions ). delay in proper management of dose-related toxicity, underventilation from any cause and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. methemoglobinemia cases of methemoglobinemia have been reported in association with local anesthetic use. although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. if local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. discontinue lidocaine hydrochloride and any other oxidizing agents. depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. a more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been postmarketing reports of chondrolysis in patients receiving such infusions. the majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. there is insufficient information to determine whether shorter infusion periods are not associated with these findings. the time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2 nd month after surgery. currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. to avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected. the needle must be repositioned until no return of blood can be elicited by aspiration. note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided. anaphylactic reactions may occur following administration of lidocaine hydrochloride (see adverse reactions ). in the case of severe reaction, discontinue the use of the drug.

Warnings: section text for external use only

Warnings for external use only flammable - keep away from fire or flame do not use with electrocautery procedures when using this product do not get into eyes apply over large areas of the body in case of deep or puncture wounds, animal bites or serious burns consult a doctor stop use and ask a doctor if condition persists or gets worse or lasts for more than 72 hours do not use longer than 1 week unless directed by a doctor keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When using this product do not get into eyes apply over large areas of the body in case of deep or puncture wounds, animal bites or serious burns consult a doctor

General the safety and effectiveness of lidocaine hydrochloride depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures. resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see warnings and adverse reactions ). the lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. syringe aspirations should also be performed before and during each supplemental injection when using indwelling catheter techniques. during the administration of epidural anesthesia, it is recommended that a test dose be administered initially and that the patient be monitored for central nervous system toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal administration, before proceeding. when clinical condition Read more...

Dosage and administration dexamethasone sodium phosphate injection, 10 mg/ml– for intravenous and intramuscular injection only. dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to sodium chloride injection or dextrose injection and administered by intravenous drip. solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant. when it is mixed with an infusion solution, sterile precautions should be observed. since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours. dosage requirements are variable and must be individualized on the basis of the disease and the response of the patient. intravenous and intramuscular injection the initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. in less severe diseases dose Read more...

Intravenous and intramuscular injection the initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. in less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required. the initial dosage should be maintained or adjusted until the patient’s response is satisfactory. if a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. after a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, Read more...

Shock there is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. the following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: author dosage cavanagh 1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg dietzman 2 2 to 6 mg/kg of body weight as a single intravenous injection frank 3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists oaks 4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists schumer 5 1 mg/kg of body weight as a single intravenous injection administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours. although adverse reactions associated with high dose, short-term corticosteroid thera Read more...

Cerebral edema dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside. response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. for palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective.

Acute allergic disorders in acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: dexamethasone sodium phosphate injection, first day , 4 or 8 mg intramuscularly. dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day , 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. this schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

Dosage and administration table 1 (recommended dosages) summarizes the recommended volumes and concentrations of lidocaine hydrochloride injection for various types of anesthetic procedures. the dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. when larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated. there have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. lidocaine hydrochloride injection is not approved for this use (see warnings and dosage and administration ). these recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. the actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of Read more...

Directions povidone iodine: tear at notch, remove applicator, use only once. as a first aid antiseptic clean affected area apply 1 to 3 times daily may be covered with a sterile bandage, if bandaged let dry. for preoperative patient skin preparation clean area apply to operative site prior to surgery using the applicator

Directions apply to skin as needed discard after single use

Stop use: if irritation and redness develop if condition persists for more than 72 hours, consult a physician.

Stop use and ask a doctor if condition persists or gets worse or lasts for more than 72 hours do not use longer than 1 week unless directed by a doctor

Contraindications systemic fungal infections (see warnings regarding amphotericin b). hypersensitivity to any component of this product (see warnings ) .

Contraindications lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

Adverse reactions fluid and electrolyte disturbances: sodium retention fluid retention congestive heart failure in susceptible patients potassium loss hypokalemic alkalosis hypertension musculoskeletal: muscle weakness steroid myopathy loss of muscle mass osteoporosis vertebral compression fractures aseptic necrosis of femoral and humeral heads tendon rupture pathologic fracture of long bones gastrointestinal: peptic ulcer with possible subsequent perforation and hemorrhage perforation of the small and large bowel; particularly in patients with inflammatory bowel disease pancreatitis abdominal distention ulcerative esophagitis dermatologic: impaired wound healing thin fragile skin petechiae and ecchymoses erythema increased sweating may suppress reactions to skin tests burning or tingling, especially in the perineal area (after iv injection) other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema neurologic: convulsions increased intracranial pressure wit Read more...

Adverse reactions systemic adverse experiences following the administration of lidocaine hydrochloride are similar in nature to those observed with other amide local anesthetic agents. these adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. serious adverse experiences are generally systemic in nature. the following types are those most commonly reported: central nervous system cns manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. the excitatory manifestations may be very brief or may Read more...

Clinically significant drug interactions the administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. concurrent use of these agents should generally be avoided. in situations when concurrent therapy is necessary, careful patient monitoring is essential. concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

Pregnancy teratogenic effects reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine hydrochloride. there are, however, no adequate and well-controlled studies in pregnant women. animal reproduction studies are not always predictive of human response. general consideration should be given to this fact before administering lidocaine hydrochloride to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

Pediatric use dosages in children should be reduced, commensurate with age, body weight and physical condition, see dosage and administration .

Overdosage reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. in the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic. the oral ld 50 of dexamethasone in female mice was 6.5 g/kg. the intravenous ld 50 of dexamethasone sodium phosphate in female mice was 794 mg/kg.

Overdosage acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see adverse reactions , warnings , and precautions ). management of local anesthetic emergencies the first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. at the first sign of change, oxygen should be administered. the first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. the clinician should be familiar, prior to the use of local anesthetics, with these anticonvulsant drugs. supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine). if not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. if cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated. dialysis is of negligible value in the treatment of acute overdosage with lidocaine hydrochloride. the oral ld 50 of lidocaine hydrochloride in non-fasted female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159 to 324) mg/kg (as the salt) in fasted female rats.

Description dexamethasone sodium phosphate injection, usp, is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly. dexamethasone sodium phosphate, usp chemically is pregna-1,4-diene-3,20-dione, 9-fluoro- 11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11ß, 16α). it occurs as a white to creamy white powder, is exceedingly hygroscopic, is soluble in water and its solutions have a ph between 7.0 and 8.5. it has the following structural formula: each ml of dexamethasone sodium phosphate injection, usp (preservative free) contains dexamethasone sodium phosphate, usp equivalent to 10 mg dexamethasone phosphate; 24.75 mg sodium citrate, dihydrate; and water for injection, q.s. ph adjusted with citric acid or sodium hydroxide, if necessary. ph: 7.0 to 8.5. structure

Description lidocaine hydrochloride injection, usp is sterile, nonpyrogenic, aqueous solution that contains a local anesthetic agent and is administered parenterally by injection. see indications and usage section for specific uses. lidocaine hydrochloride injection, usp contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular weight 270.8. lidocaine hydrochloride (c 14 h 22 n 2 o • hcl) has the following structural formula: lidocaine hydrochloride injection, usp is a sterile, nonpyrogenic, isotonic solution containing sodium chloride. the ph of the solution is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid. lidocaine chemical structure

Clinical pharmacology dexamethasone sodium phosphate injection has a rapid onset but short duration of action when compared with less soluble preparations. because of this, it is suitable for the treatment of acute disorders responsive to adrenocortical steroid therapy. naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. glucocorticoids cause profound and varied metabolic effects. in addition, they modify the body’s immune responses to diverse stimuli. at equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.

Clinical pharmacology mechanism of action lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. hemodynamics excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. with central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present. the net effect is normally a modest hypotension when the recommended dosages are not exceeded. pharmacokinetics and metabolism information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of Read more...

Carcinogenesis, mutagenesis, impairment of fertility studies of lidocaine hydrochloride in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

How supplied dexamethasone sodium phosphate injection, usp (preservative free) equivalent to 10 mg dexamethasone phosphate, is supplied in a single dose vial as follows: product no. ndc no. strength vial size 500601 63323-506-01 10 mg per ml 1 ml vial, packaged in twenty-fives. this container closure is not made with natural rubber latex. storage store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. sensitive to heat. do not autoclave. protect from freezing. protect from light. single dose vials–store in container until time of use. discard unused portion.

Storage store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. sensitive to heat. do not autoclave. protect from freezing. protect from light. single dose vials–store in container until time of use. discard unused portion.

How supplied lidocaine hydrochloride injection usp, is supplied as follows: lidocaine hydrochloride injection usp, 1% (10 mg/ml) 2 ml ampules in a carton of 10 ndc 55150-158-72 sterile, nonpyrogenic discard unused portion. store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. distributed by: auromedics pharma llc 279 princeton-hightstown rd. e. windsor, nj 08520 manufactured by: eugia pharma specialities limited hyderabad - 500032 india revised: october 2021

Information for patients when appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia. inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

Prncipal display panel ndc: 76420-767-01 rx only dexlido™ kit contains 1 dexamethasone sodium phosphate inj., usp 10mg/ml (1ml) 1 lidocaine hcl injection, usp 1% ampule (2ml) 1 povidone-iodine swabsticks (3 swabs) 2 isopropyl alcohol 70% prep pads 1 pair nitrile powder free sterile gloves (m) 1 drape 1 adhesive bandage 5 non sterile 4x4 gauze needles and syringes not included 1 dose single use only distributed by: enovachem™ pharmaceuticals torrance, ca 90501 principal display panel – kit label